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Introduction: During the last decade, a number of meta-analyses questioned the clinically relevant efficacy of
antidepressants. Part of the debate concerned the method used in each of these meta-analyses as well as the
quality of the data set.
Materials and methods: The Kirsch data set was analysed with a number of different methods, and eight key
questions were tackled. We fit random effects models in both Bayesian and frequentist statistical frameworks using
raw mean difference and standardised mean difference scales. We also compare between-study heterogeneity
estimates and produce treatment rank probabilities for all antidepressants. The role of the initial severity is further
examined using meta-regression methods.
Results: The results suggest that antidepressants have a standardised effect size equal to 0.34 which is lower but
comparable to the effect of antipsychotics in schizophrenia and acute mania. The raw HDRS difference from
placebo is 2.82 with the value of 3 included in the confidence interval (2.21–3.44). No role of initial severity was
found after partially controlling for the effect of structural (mathematical) coupling. Although data are not definite,
even after controlling for baseline severity, there is a strong possibility that venlafaxine is superior to fluoxetine, with
the other two agents positioned in the middle. The decrease in the difference between the agent and placebo in
more recent studies in comparison to older ones is attributed to baseline severity alone.
Discussion: The results reported here conclude the debate on the efficacy of antidepressants and suggest that
antidepressants are clearly superior to placebo. They also suggest that baseline severity cannot be utilized to dictate
whether the treatment should include medication or not. Suggestions like this, proposed by guidelines or
institutions (e.g. the NICE), should be considered mistaken.
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Recently, a number of meta-analytic studies questioned
the clinical usefulness of antidepressants. It has been
shown that there is a significant bias in the publication
of antidepressant trials [1] and that the effect size of the
medication group in comparison to that of the placebo
is rather small [2-9]. On the basis of these results, a
‘conspiracy theory’ involving the Food and Drug Admin-
istration (FDA) was proposed [10,11]. Furthermore, by
‘overstretching’ the interpretation of the data, it has been
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distribution, and reproduction in any mediumalternative therapies (e.g. exercise and psychotherapy)
may be a better treatment choice for depression [10].
These triggered much interest from the mass media and
from intellects outside the mental health area, often with
a biased and ideologically loaded approach [12]. How-
ever, the most important suggestion was that initial se-
verity plays a major role and antidepressants might not
have any effect at all in mildly depressed patients [5,6,8].
Following this conclusion, several authors and agencies
like the National Institute of Clinical Excellence (NICE)
suggested the utilisation of ‘alternative’ treatment op-
tions (e.g. exercise and psychotherapy) in mildly de-
pressed patients and pharmacotherapy only for the most
severe cases. Among other things, these authors andentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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arly, similar findings were reported concerning psycho-
therapy [13-16].
Several authors criticised the above by focusing on the
limitations of randomised clinical trials (RCTs), on clin-
ical issues and, especially, on the problematic properties
of the Hamilton depression rating scale (HDRS) and on
the fact that the effectiveness of antidepressants in clin-
ical practice is normally optimised by sequential and
combined therapy approaches. It has been proposed that
the effect is significant in a subgroup of patients [17]. So
far, only two efforts were made to re-analyse the same





Simple random effects meta-analysis 2.71 (1.96,
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Turner et al. (random effects meta-analysis) - 0.3
Khan et al., ratio of the number of early discontinued
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-
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Simple random effects meta-regression analysis 2.77 (2.18,
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Simple random effects meta-regression analysis using
12 different priors
NMA random effects meta-regression analysis
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Using the raw mean difference (RMD) and standardised mean difference (SMD) und
variable is provided with its confidence interval (CI) and in the Bayesian methods w
association with the role for initial severity and its respect to randomisation.[18,19]. These two efforts independently reported the re-
sults that are quite similar between them but different
from those of the study of Kirsch et al.
All the meta-analytic studies mentioned above were
based on five ‘data sets’. The data sets are the Khan
et al. set [8,20], the Turner et al. set [1], the Kirsch et al.
set [5], the Fournier et al. set [6] and the Undurraga and
Baldessarini set [9].
All the meta-analyses are shown in Table 1 with
respect to the methodology used and results. In this
table, Undurraga and Baldessarini [9] was not included
because these authors utilised a different outcome meas-
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er both frequentist and Bayesian methods. In the frequentist approach, each
ith its credible interval (CrI). Each method is categorised according to its
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includes primary care patients with dysthymia
and major depressive patients who accepted to be
randomised to medication, psychotherapy or placebo,
fixed as well as flexible dosage studies and medication
up to 50 mg of paroxetine but only up to 100 mg of
imipramine [21-25]. It is interesting that a common
denominator of the studies included in this specific
meta-analysis was that the efficacy of psychosocial inter-
ventions depends also on initial severity, the same way
the medication does. In the Unduraga and Baldessarini
set, variance measures are missing in many trials. How-
ever, in the Khan et al. data set, only 21 out of 45 studies
reported a standard error of measurement or a standard
deviation of mean change. The data of the Turner et al.
set are not available to the authors of the current paper
except for the effect sizes of individual studies. On the
other hand, the Kirsch et al. set is more complete and
available online.
The data set of Kirsch et al. [5] might serve as a para-
digm since it has been independently re-analysed by two
other groups [18,19] and is based on FDA data which
seem to be free of bias [26]. Thus, the current study will
utilise the Kirsch et al. (reference) data set and will focus
on the debate following its analysis and re-analysis.
It is important to define the specific questions that
arise from the debate. According to our judgement, they
are the following:
1. What is the bias in the Kirsch data set? How
complete is this data set?
2. What is the magnitude of the heterogeneity (τ2) of
the studies in this data set?
3. Which is the most appropriate method for meta-
analysis of this data set?
4. What is the standardised mean difference (SMD) for
the efficacy of antidepressants vs. placebo?
5. What is the raw HDRS mean difference (RMD) for
the efficacy of antidepressants vs. placebo?
6. Is the SMD or the raw score more appropriate to
reflect the difference between the active drug and
the placebo?
7. Are all antidepressants equal in terms of efficacy?
8. What is the role of the initial severity?
9. Is there a change in the difference between active
drug and placebo in more recent RCTs in
comparison to older ones?
There is some hierarchical interrelationship between
the aforementioned questions, which requires sequen-
tial answers in order to clarify the issue. The current
paper will tackle these questions and will try to provide
answers with the use of multiple methods of meta-
analysis.Materials and methods
The Kirsch et al. database as published by these authors
[27] was used in the current analysis. The complete set
used in the current study is shown in Additional file 1.
Since one element of the debate was the use of differ-
ent methods of meta-analysis, a number of methods
were used in the current study and their results were
compared. These were (a) simple random effects (RE)
meta-analysis (simple REMA), (b) network RE meta-
analysis (NMA), (c) simple RE meta-regression and
(d) NMA RE meta-regression, in both Bayesian and
frequentist frameworks. The description, advantages and
disadvantages of each of these methods can be found in
Additional file 2.
All approaches have been undertaken under the RE
model [28-30], so as to account for between-study het-
erogeneity due to the differences in the true effect sizes,
rather than chance. We selected the RE meta-analysis
since our prior belief was that treatment effects vary
across studies, and our aim was to infer on the distribu-
tion of the effects. In case there is no statistical variabil-
ity in the effects, RE model simplifies to fixed effects
model with τ2 equal to zero. We further applied meta-
regression methods for the synthesis of the data, as it al-
lows for the inclusion of study-level covariates that may
explain the presence of heterogeneity. We explored
whether two moderators, the initial severity and publica-
tion year, were associated with the treatment effect. One
of the studies in the database was considered by Kirsch
et al. to be an outlier. We therefore performed all meta-
regression analyses with and without this particular
study. In NMA models, we ranked all antidepressants
using the probability of being the best [31] in the
frequentist setting and the cumulative ranking probabil-
ities in the Bayesian framework [32]. All methods were
carried out employing both RMD and SMD scales.
The main differences between Bayesian and frequentist
methods regard the estimation of heterogeneity. In
meta-analysis, the choice of the method for estimating
heterogeneity is a great issue since imprecise or biased
approaches might lead to invalid results. Several
methods have been suggested for estimating heterogen-
eity. In the frequentist methods, we estimated a ‘fixed’
parameter of the heterogeneity and we employed the
commonly used DerSimonian and Laird (DL), or in case
DL was not available, we performed the popular re-
stricted maximum likelihood estimator. In the Bayesian
framework, we accounted for the uncertainty in the esti-
mation of heterogeneity, assuming it is a random vari-
able. The magnitude of uncertainty associated with
heterogeneity is included in the results and may have a
considerable impact on our inferences. However, the
Bayesian estimation of the heterogeneity under different
prior selections for τ2 can be shown problematic when
Fountoulakis et al. Annals of General Psychiatry 2013, 12:26 Page 4 of 10
http://www.annals-general-psychiatry.com/content/12/1/26few studies are available [33,34]. We therefore consider
12 different prior distributions for the heterogeneity in
the NMA RE meta-regression model so as to evaluate
any possible differences in the results.
Results
The complete results of the analyses are shown in
Additional file 3.
What is the bias in the Kirsch data set? How complete is
this data set?
The funnel plots (Section 1 in Additional file 3) according
to both RMD and SMD, treatment effects suggest that
there is no asymmetry in the way the data points lie within
the region defined by the two diagonal lines, which repre-
sent the 95% confidence limits around the summary treat-
ment effect. Thus, there is no evidence for the presence of
bias, as both funnel plots are visually symmetrical.
What is the magnitude of the heterogeneity of the
studies in this data set?
All RMD analyses showed the presence of important
heterogeneity, and all RMD Bayesian approaches apart
from simple RE meta-regression analysis showed that τ2
is significantly greater than zero. On the contrary, SMD
exhibited lower and not statistically significant hetero-
geneity. This is in agreement with previous empirical
findings [35] suggesting that SMD is more consistent
than RMD as baseline varies. To investigate the presence
of heterogeneity, we employed the RE meta-regression
analysis with initial severity as a covariate. The RMD RE
meta-regression analysis reduced the magnitude of het-
erogeneity, suggesting that initial severity explains part
of the magnitude of the heterogeneity, whereas SMD
suggests that initial severity does not play a significant
role in the variance of the treatment effects.
The magnitude of heterogeneity when the SMD RE
meta-regression model was employed with 12 different
prior distributions for τ2 ranged in between 0.00 and
0.04 with all cases apart from the weakly informative
gamma prior distribution being not statistically signifi-
cant. However, the RMD heterogeneity ranged in be-
tween 0.24 and 1.29 with all credible intervals, apart
from the two non-informative uniform priors for the
logarithm of τ2, being significantly greater than zero. We
therefore observe that RMD scale is sensitive in the
prior selection of τ2, which impacts on the results and
may lead to different statistical inferences. The two
scales suggest different results regarding the magnitude
of heterogeneity due to their different properties. The
heterogeneity of the data according to different methods
is shown in detail in Section 2 in Additional file 3. The
estimation of heterogeneity is important in choosing the
appropriate model for the analysis of data [33,34].Which is the most appropriate method for meta-analysis
of this data set?
The selection of the effect size relying only on the mag-
nitude of heterogeneity is not appropriate and can be
shown problematic. It is suggested that the choice of the
effect measure should be guided by empirical evidence
and clinical expertise. Empirical investigations have
shown that the SMD scale is less heterogeneous than
RMD and that gives more reliable results as baseline
risks vary, which is in agreement with our findings.
However, it has been found that the SMD for small trials
(number of included patients per group less than 10)
bias the results towards to the null value in around 5%–
6% of the cases even when the small sample correction
factor is used [35]. Although this bias can contribute to
the decreased heterogeneity of SMD, in our data set, all
study arms apart from one included more than 10 pa-
tients. In our different analyses, the SMD scale was more
consistent than the RMD, suggesting more valid results.
Although simple RE meta-analysis provides the most
reliable evidence, it only gives insights on the effective-
ness between the two treatments. Our data set includes
evidence on multiple interventions, and the need to
compare and rank these treatments suggests the use of
NMA. However, the presence of heterogeneity in NMA
analysis should be investigated. We therefore explore
any possible reasons for its presence by employing NMA
RE meta-regression with initial severity as covariate.
However, since initial severity forms part of the
definition of both SMD and RMD, there is a strong rela-
tionship between the covariate and the effect size (math-
ematical coupling). It is therefore very likely in the
frequentist setting to find a significant relationship be-
tween initial severity and treatment effectiveness. In the
Bayesian setting though, we ‘correct’ for this artefact by
adjusting towards the global mean [36-39]. In the Bayes-
ian NMA RE meta-regression model, we assume a fixed
coefficient (β) for all treatment comparisons and we as-
sign to it an uninformative prior. The method is more
powerful than carrying out several independent pairwise
meta-regressions.
We therefore conclude that Bayesian NMA RE meta-
regression model using the most consistent scale (SMD)
is the most appropriate method to meta-analyse these
data.
What is the SMD for the efficacy of antidepressants
vs. placebo?
The SMD in simple RE meta-analysis under the
frequentist approach is 0.33 (0.24–0.42) and under the
Bayesian approach is 0.32 (0.25–0.40). Accounting for
initial severity in all antidepressants, we apply a simple
RE meta-regression analysis reflecting an SMD under
the Bayesian approach at 0.34 (0.27–0.42), which does
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essence, all methods give a similar SMD value (see
Sections 4 and 5 in Additional file 3).
What is the raw HDRS mean difference for the efficacy of
antidepressants vs. placebo?
The RMD in the simple RE meta-analysis under the
frequentist approach is 2.71 (1.96–3.45) and under the
Bayesian approach is 2.61 (1.94–3.30). We investigate
the relationship between initial severity and treatment
efficacy via the simple RE meta-regression analysis which
under the Bayesian approach gives an RMD at 2.77
(2.18–3.36). After excluding the outlier, the raw HDRS
value is 2.82 (2.21–3.44) (see Sections 4 and 5 in
Additional file 3).
Again, all methods give a similar result, and all confi-
dence intervals extend above the value of 3 which repre-
sents the NICE criterion for clinical relevance.
Is the SMD or the raw score more appropriate to reflect
the difference between the active drug and the placebo?
As written above, the use of SMD with a Bayesian
approach would be the most appropriate method to
meta-analyse these data, since it is associated with the
least heterogeneity.
Are all antidepressants equal in terms of efficacy?
The comparison of antidepressants with placebo as ref-
erence suggests that according to all methods used, all
antidepressants are superior to placebo.
Venlafaxine is probably the most effective followed
by paroxetine, while fluoxetine is the least effective
according to all analyses, except for NMA RE meta-
regression using RMD that suggests venlafaxine and
nefazodone are similar and more effective than the
others.
The hierarchical classification of agents has been done
by the use of SUCRA values in the Bayesian analysis [40]
or the posterior probabilities in the frequentist analysis
[31]. Although both methods give insight on the ranking
of treatments, the Bayesian approach using SUCRA
values would be the most valid method. The main differ-
ence between SUCRA values and the probability of each
treatment to be the best is that the former takes into ac-
count the uncertainty around the mean of the distribu-
tion of the effects, whereas the latter relies only on the
mean of the distribution. Although confidence intervals
overlap, SUCRA values give a strong probability of
which agent performs better. The fact that confidence
intervals overlap puts doubt on whether there is a true
difference between agents.
NMA methods using RMD measure suggest that flu-
oxetine is clearly inferior to venlafaxine, since credible
intervals of these two agents do not overlap. Similarly,the SMD scale suggests that venlafaxine is superior to all
antidepressants but not significantly different (see Sec-
tion 7 in Additional file 3).What is the role of the initial severity?
When the RMD is used in the calculations, both
frequentist and Bayesian methods suggest a significant
influence of the initial severity. This, also, explains the
reduction of the amount of the heterogeneity from sim-
ple RE meta-analysis to simple RE meta-regression and
from NMA to NMA RE meta-regression analysis.
However, when the SMD is considered, the frequentist
simple RE meta-regression suggests a significant influ-
ence for initial severity, while in contrast, the Bayesian
methods (simple RE meta-regression and NMA RE
meta-regression) suggest no such an influence exists. It
is possible that different effect sizes can lead to different
inferences regarding baseline. Relying on the Cochrane
Handbook, the effect size that is ‘close to no relationship
with baseline risk is generally preferred for use in meta-
analysis’. Moreover, the investigation of the relationship
between treatment effects and initial severity under the
frequentist methods can lead to inappropriate results,
since they are inherently correlated [36]. However, the
use of uninformative prior distribution for the regression
coefficient and the adjustment for the mean baseline in
the Bayesian setting relaxes the strong correlation be-
tween the treatment effect and the initial severity
resulting in more reliable inferences for this relationship
[36]. The results under the SMD effect measure suggest
that there is no significant role of initial severity in the
treatment outcome.Is there a change in the difference between active
drug and placebo in more recent RCTs in comparison
to older ones?
Although there seems to be a change in the difference
between the active drug and placebo in more recent
RCTs in comparison to older ones, the use of simple RE
meta-regression with two covariates (initial severity and
year of publication) using either RMD or SMD suggests
that the year of publication is not important while initial
severity is. This means that the attenuated difference can
be attributed to a lower initial severity in newer RCTs in
comparison to older ones.
The use of the ‘year of publication’ is an arbitrary vari-
able. Alternatively, we could have used only the two last
digits of it or the years since the oldest trial included. At
any case, this analysis gives only a hint that initial sever-
ity is important and not the years passed (reflecting
change in other factors). A method to quantify the years
passed (except from the arbitrary year of publication) is
an unanswered question.
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For the last 10 years, after the Khan et al. meta-analysis,
and especially after the Kirsch et al. publication [5,8], the
efficacy of antidepressants in the treatment of major de-
pression was under dispute. The current multi-meta-
analysis utilised the Kirsch et al. data set and suggests
that the most appropriate methods to meta-analyse these
data are RE meta-regression models in a Bayesian setting
using the SMD scale. It is important to decide which
method of meta-analysis is best for the current data set,
since different methods and different effect measures
have different properties and can therefore result in
different estimates [35,41,42].
The use of SMD in a Bayesian RE meta-regression
model suggests that the standardised effect size of anti-
depressants relative to placebo is 0.34 (0.27–0.42), and
there is no significant role for the initial severity of
depression. The most probable raw HDRS change score
is 2.82 (2.21–3.44) extending above 3. Our analysis
showed that antidepressants are not equally effective.
Bayesian NMA approaches suggest that venlafaxine is
more effective than the rest with fluoxetine being the
least effective among antidepressants.
The Kirsch hypothesis concerning depression is that
there is a response which lies on a continuum from no
intervention at all (e.g. waiting lists) to neutral placebo,
then to active and augmented placebo including psycho-
therapy and finally to antidepressants which exert a
slightly higher efficacy probably because blinding is im-
perfect because of the side effects (enhanced placebo)
[10,43-48]. The full theory of Kirsch and its criticism
can be found elsewhere [49,50].
The meta-analytical methods applied so far have ad-
vantages and limitations and much of the discussion fo-
cused on these limitations, and biases are introduced
(Table 1). In the analysis of Kirsch et al. [5], the authors
calculated the mean in drug change and the mean in
placebo change and then took their difference. This
breaks the randomisation and introduces bias, as it ig-
nores the studies' characteristics and the sample size
[51-53]. The so-called naïve comparisons are liable to
bias and overprecise estimates. Horder et al. [19] used
simple meta-analysis in a frequentist approach. They
used standard meta-analytic approaches (fixed and ran-
dom effects meta-analysis) and applied meta-regression
in frequentist approach where the drug change vs. pla-
cebo change is plotted. Meta-regression, the way they
used it, also breaks the randomisation as it does not ac-
count for the correlation between the change in placebo
and the change in drug. Fountoulakis and Moller [18]
used two methods: (a) sample size weighting which is
appropriate when a set of independent effect sizes (e.g.
RMD, SMD) is combined, but again, it breaks the ran-
domisation and introduces bias. (b) Inverse varianceweighting which applies weight as the inverse variance
or the precision of each arm in each study. The preci-
sion of the effect estimates is the most accurate estima-
tion of the summary effect size. It calculates the
standardised change both for drug and placebo and then
takes their difference. However, this again breaks the
randomisation and introduces bias. Khan et al. [8] ap-
plied simple regression in frequentist approach where
the drug change vs. baseline is plotted and the correl-
ation coefficient is calculated. However, the precision of
each study and the heterogeneity is not taken into ac-
count as in a meta-regression analysis. Then, in order to
draw conclusions, the authors divided the sum of the
number of early discontinued patients by the sum of the
number of total patients in each arm and then calculated
the chi-square. This is not an appropriate analysis as it
also breaks the randomisation.
We believe that the current paper resolves the debate
concerning the efficacy of antidepressants and its pos-
sible relationship to the initial severity in a definite
manner.
The argument that an SMD of 0.30–0.35 is a weak one
and suggests that the treatment is not really working or
it does not make any clinically relevant difference
neglects the fact that such an effect size is the rule ra-
ther than the exception [54]. Traditionally, an SMD of
around 0.2 is considered to be small, around 0.5 is con-
sidered medium and around 0.8 is considered to be large
[55], but this is an arbitrary assumption. However, in the
real world of therapeutics, things are quite different. For
comparison, one should look at the acute mania meta-
analyses which suggest an SMD of 0.22 [56] or 0.42 [57],
while clinically, acute mania is one of the easiest-to-treat
acute psychiatric conditions. Also, the SMD of antipsy-
chotics against the positive symptoms of schizophrenia
is 0.48 [58].
The present study suggests that in this data set, the
SMD results in more meaningful inferences than the
RMD effect measure, since a greater amount of hetero-
geneity is produced using RMD. However, all calcula-
tions of RMD suggested a mean close to 3 and
confidence intervals including the value of 3, thus
suggesting that the RMD is not lower than the suggested
NICE criterion. However, this criterion is arbitrary and
unscientific, both in terms of clinical experience as well
as in mathematical terms (because of the mathematical
coupling phenomenon, see below), but this discussion is
beyond the scope of the current paper [59,60].
Because the earlier meta-analyses suggested that initial
severity is related to outcome with more severe cases
responding better to antidepressants in comparison to
placebo, some authors suggested that medication might
not work at all for mildly depressed patients. Thus, they
argued that for these patients, medication should not be
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sumably lack side effects should be preferred, in spite of
the possibility that the difference between medication
and psychotherapy is similar to that between medication
and placebo [61]. The suggestion to avoid pharmaco-
therapy in cases of mild depression is adopted also by
the most recent NICE guidelines CG90. An immediate
consequence of this is that patients suffering from mild
depression are deprived from receiving antidepressants,
on the basis of this conclusion and the overvaluation of
‘alternative therapies’.
‘Common sense’ among physicians leads to the belief
that patients with greater disease severity at baseline re-
spond better to treatment. The relation between baseline
disease severity and treatment effect has a generic name
in the statistical literature: ‘the relation between change
and initial value’ [62] because treatment effect is evalu-
ated by measuring the change of variables from their ini-
tial (baseline) values. In psychology, it is also well known
as the ‘law of initial value’ [63].
However, the concept of ‘mathematical coupling’,
which was demonstrated for the first time by Oldham in
1962, suggests that there is a strong structural correl-
ation (approximately 0.71) between the baseline values
and change, even when ‘change’ is calculated on the
basis of two columns of random numbers [59]. Mathem-
atical coupling can lead to an artificially inflated associ-
ation between initial value and change score when naïve
methods are used [60]. The problem is that Bayesian
methods, which are able to partially correct for this
artefact to a significant degree, are not routinely applied
in meta-analytic paper researches [64-66]. However,
even these methods are not completely free from this
phenomenon.
Taking into account that our data form a ‘star-shaped’
network, where all agents are compared to placebo ef-
fect, we employed a more advanced statistical method
than other authors in the past, which is the NMA that is
calculated for all treatments, the probability of being the
best [31], and the SUCRA values [32]. In our case (star
network pattern), NMA method relies only on the
indirect comparison via placebo to contrast the different
agents. In comparison, Huedo-Medina et al. [27]
employed the naïve method of pooling the results, which
has been criticised in meta-analysis bibliography that is
liable to bias [53]. Conclusively, the results of the
current paper suggesting that the use of Bayesian ap-
proach returns no role for initial severity should be
considered to be strong. This finding is in accord with
the conclusion other authors reached by analysing
different data sets [67,68].
An important limitation in the Kirsch et al. data set is
that it includes aggregate data rather than individual pa-
tient data. It has been recently shown that inference onpatient-level characteristics, such as initial severity, using
meta-regression models and aggregated evidence can be
problematic due to aggregation bias [69]. As clearly
stated in Additional file 2 (simple meta-regression in
Section 3), this method has low power to detect any re-
lationship when the number of studies is small.
A more complex issue which is beyond the scope of
the current article is the intrinsic problems in the meth-
odology of RCTs [70]. These problems tend to reduce
the effect size for a number of reasons, with most prom-
inent being the quality of recruited patients and the
problems with the quantification of psychiatric symp-
toms, including the psychometric properties of the scales
used. Even the concept of ‘severity’ is not satisfactorily
studied. For example, some items like ‘depressed mood’
manifest a ceiling effect as severity grows while others
like ‘suicidality’ manifest a floor effect as severity is re-
duced [71-81]. Both the HDRS and the MADRS describe
a construct of depression which corresponds poorly to
that defined by the DSM-IV and ICD-10 and include
items corresponding to non-specific symptoms (e.g.
sleep, appetite, anxiety; they might respond to a variety
of non-antidepressant agents) or even side-effects (e.g.
somatic symptoms) [77,78,82]. Also, it is obvious that
the last observation carried forward method significantly
contaminates efficacy with tolerability. However, no
other results are usually available to analyse. Taking to-
gether that in many RCTs, agents like benzodiazepines
are permitted in the placebo arm, the final score might
not reflect the actual effect of the drug vs. placebo per se
but somehow the add-on value of antidepressants on
benzodiazepines. The RCTs are necessary for the licens-
ing of drugs as safe and effective by the FDA, the EMEA,
the MHRA, etc., but their usefulness should not be
overstated, and their data should not be overused.
Maybe it is time the raw data to be in the public domain,
at least for products whose patent has expired. The way
the lay press and especially the way medical scientists
write for the lay press concerning antidepressants
[83,84] cannot be considered in any other way but as be-
ing a reflection of a new type of stigma for depressed
patients.
The results of the current study also suggest there is
no ‘year’ effect; however, the changing severity of pa-
tients recruited over the years might result in a change
in the observed difference between placebo and active
drug. This is largely in accord with the conclusions of
Undurraga and Baldessarini [9].
Conclusion
The series of meta-analysis performed during the last
decade made antidepressants maybe the best meta-
analytically studied class of drugs in the whole of medi-
cine. The results of the current analysis conclude the
Fountoulakis et al. Annals of General Psychiatry 2013, 12:26 Page 8 of 10
http://www.annals-general-psychiatry.com/content/12/1/26debate and suggest that antidepressants are clearly
superior to placebo, and their efficacy is unrelated to ini-
tial severity. Thus, there is no scientific ground to deny
mildly depressed patients the use of antidepressants,
especially since they constitute the best validated treat-
ment option for depression.
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